Multiple factors lead to pressure on pharmaceutical export enterprises

Despite the slow recovery of global pharmaceutical trade volume from last year's low, domestic exhibitors and foreign purchasers did not make a positive deal at the 114th Canton Fair due to multiple factors such as policy adjustment, intensified competition, increased foreign trade frictions and rising costs As the biggest competitor of made in China, the continuous depreciation of Indian rupee has promoted the export of pharmaceutical products to a certain extent and diverted some orders of Chinese pharmaceutical enterprises with price advantage Similar to the previous two periods, the pharmaceutical enterprises participating in the third period generally reported that the number of overseas purchasers attending the meeting decreased, and the order and transaction price were not ideal Chen Kang, director of the general manager's office of Shanghai Medical and health products import and Export Co., Ltd., said that the company's booth in Guangzhou Fair is a good place, but there are not many purchasers coming to the booth, and it is estimated that the situation of some small and medium-sized enterprises is even worse Due to many uncertain factors, the enterprise is very cautious in receiving orders this time "Recently, there has been an increase in orders, some of which have been scheduled for February to March next year, but we are also consciously controlling the number of orders to avoid failing to deliver the goods at that time." Chen Kang said that this year, the state strengthened the supervision and inspection of the implementation of GMP by enterprises Some pharmaceutical enterprises failed to pass the customs and closed down, while some were still in the process of rectification As a result, the production capacity of drugs has been reduced, and the prices of operating pharmaceutical factories have generally been raised, and it is not necessary to deliver drugs on time In addition, the price also gives Chen Kang a headache He said that the company's exports have been the same as last year's, but its profits have fallen sharply On the one hand, the appreciation of RMB and the rise of labor cost have eroded certain profits; on the other hand, India, which is also a big exporter of pharmaceutical products, is pushing down the price of products "Although the cost is rising, the price of some drugs has fallen sharply For example, the export price of vitamin C has dropped from several tens of dollars per kilogram in previous years to several dollars per kilogram Many enterprises are already losing money if they do not include export tax rebate." Chen Kang lamented that the export business is becoming more and more difficult, and hoped that the state could introduce relevant policies to guide the industry to develop in a healthy way In 2012, China's pharmaceutical import and export volume reached US $81.3 billion, an increase of more than eight times over 10 years ago, of which the export volume increased from US $5.4 billion to US $47.9 billion China's pharmaceutical foreign trade has grown by leaps and bounds, which has aroused the vigilance of relevant foreign industries In recent years, trade frictions on the whole have increased In 2013, global pharmaceutical trade recovered slowly from last year's low In the first half of this year, exports reached 495 billion US dollars, a slight increase of 2.46% However, at present, the recovery of major economies such as Europe and the United States is still weak, and a wave of "Reindustrialization" is set off The competition among emerging countries, such as India, is becoming increasingly fierce in low-end pharmaceutical products, and the foreign trade environment is still complex In this regard, the China Chamber of Commerce for import and export of pharmaceutical and health care products suggests that enterprises should not only consolidate the traditional pharmaceutical market, but also vigorously develop new markets, seize the critical period when "patent drugs" expire, strive for a feast of generic drugs, and strengthen the ability of independent research and development According to the chamber of Commerce for import and export, at present, domestic leading pharmaceutical enterprises have obtained a large number of foreign generic API certification, and gradually upgraded to independent research and development, patent challenge of pharmaceutical export mode Some domestic pharmaceutical enterprises export preparations to Europe with patent challenges and successfully register in the EU Some enterprises have accumulated capital, technology and other aspects in the domestic generic market, so they can directly submit applications to the US FDA, and the generic drugs are likely to be exported in a one-step manner.